MonTa Biosciences attend the AngloNordic Life science conference in London on Mya 24th to meet investors and network [...]
MonTa Biosciences attend the Biotechandmoney conference in London on February 5-6. [...]
MonTa Biosciences attends the BioEurope partnering conference in Berlin from November 4-8. Please book a meeting with [...]
MonTa Biosciences announces completion of license agreements with UC San Diego and Danish Technical University. The immune [...]
MonTa Biosciences attends the Nordic Life Science Days in Malmö to meet with investors and pharma partners. [...]
MonTa Biosciences recruits PhD, Esper Boel former SVP in Novo Nordisk and strategic adviosor in immunotherapy to its Board [...]
MonTa Biosciences attends BioEurope Spring in Barcelona to have meetings with more than 10 of the top [...]
MonTa Biosciences closes an investment from Pre-Seed Innovation to reach key milestones for our cancer [...]
MonTa Biosciences join the NOME Mentoring programme in the North Carolina Research Triangle and are appointed top [...]
MonTa Biosciences awarded to be included in the NOME Nordic Mentoring Network for Entrepreneurship. MonTa Biosciences is priviledged to be part [...]
A news article was published by the Danish Biotech media; Medwatch on the newly granted [...]
MonTa Biosciences is part of the XVac “Grand Solutions” granted an Investment from “Innovationsfonden”. The XVac project [...]
MonTa Biosciences Co-founder Thomas L Andresen talks in Danish national radio about the cancer immunotehrapy [...]
MedWatch publishes article on MonTa Biosciences. [...]
The monocyte targeting technology was published in an article in “Expert Opinion in Drug Delivery”. [...]
MonTa Biosciences was awarded a “Proof-of-Concept” grant from Copenhagen Spin-puts” to support the early development [...]
An article about MonTa Biosciences was published in Medwatch on April 8, 2014. [...]
The MonTa Biosciences’ technology was presented at the Society for Immunotherapy of Cancer “SITC” in National harbour, [...]
